Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform.

CAMBRIDGE, Mass. and SAN FRANCISCO, Sept. 17, 2025 /PRNewswire/ -- The laboratories of Dr. Kevin Bender and Dr. Nadav Ahituv at the University of California, San Francisco, today announced the publication of preclinical proof-of-concept data demonstrating that CRISPR activation restores...